98%
921
2 minutes
20
Infants with hypoplastic left heart syndrome require an initial Norwood operation, followed some months later by a stage 2 palliation (S2P). The timing of S2P is critical for the operation's success and the infant's survival, but the optimal timing, if one exists, is unknown. We attempt to identify the optimal timing of S2P by analyzing data from the Single Ventricle Reconstruction Trial (SVRT), which randomized patients between two different types of Norwood procedure. In the SVRT, the timing of the S2P was chosen by the medical team; thus with respect to this exposure, the trial constitutes an observational study, and the analysis must adjust for potential confounding. To accomplish this, we propose an extended propensity score analysis that describes the time to surgery as a function of confounders in a discrete competing-risk model. We then apply inverse probability weighting to estimate a spline hazard model for predicting survival from the time of S2P. Our analysis suggests that S2P conducted at 6 months after the Norwood gives the patient the best post-S2P survival. Thus, we place the optimal time slightly later than a previous analysis in the medical literature that did not account for competing risks of death and heart transplantation.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/biom.13311 | DOI Listing |
Bull Math Biol
September 2025
Wolfson Centre for Mathematical Biology, Mathematical Institute, Oxford, UK.
Adaptive therapy (AT) protocols have been introduced to combat drug resistance in cancer, and are characterized by breaks from maximum tolerated dose treatment (the current standard of care in most clinical settings). These breaks are scheduled to maintain tolerably high levels of tumor burden, employing competitive suppression of treatment-resistant sub-populations by treatment-sensitive sub-populations. AT has been integrated into several ongoing or planned clinical trials, including treatment of metastatic castrate-resistant prostate cancer, ovarian cancer, and BRAF-mutant melanoma, with initial clinical results suggesting that it can offer significant extensions in the time to progression over the standard of care.
View Article and Find Full Text PDFPediatr Nephrol
September 2025
Department of Pediatric Critical Care, Ankara University School of Medicine, Ankara, Turkey.
Background: This retrospective, descriptive study, conducted in a single-center PICU from June 2014 to May 2023, aimed to analyze the efficacy of adjunctive regional citrate anticoagulation for continuous kidney replacement therapy (CKRT) circuits during extracorporeal membrane oxygenation (ECMO).
Methods: Patients were divided into two groups based on their CKRT anticoagulation strategy: those receiving regional citrate anticoagulation in addition to systemic heparin (UFH + RCA group) and those receiving only systemic heparin (UFH group). CKRT circuits were also classified as either UFH + RCA or UFH to analyze outcomes specific to each anticoagulation strategy.
Semin Vasc Surg
September 2025
Division of Vascular and Endovascular Surgery, Department of Surgery, Stony Brook University Hospital, Health Sciences Tower, Stony Brook, NY, 11794. Electronic address:
Chronic mesenteric ischemia (CMI) is a rare, yet increasingly prevalent, condition, especially among older adults. Diagnosing CMI in older adults presents significant challenges. Along with the burden of comorbidities and the physiological changes associated with aging, timely intervention is often delayed, leading to poorer outcomes.
View Article and Find Full Text PDFJMIR Med Inform
September 2025
Department of Hepatobiliary and Vascular Surgery, First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
Background: Primary liver cancer, particularly hepatocellular carcinoma (HCC), poses significant clinical challenges due to late-stage diagnosis, tumor heterogeneity, and rapidly evolving therapeutic strategies. While systematic reviews and meta-analyses are essential for updating clinical guidelines, their labor-intensive nature limits timely evidence synthesis.
Objective: This study proposes an automated literature screening workflow powered by large language models (LLMs) to accelerate evidence synthesis for HCC treatment guidelines.
Blood Adv
September 2025
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States.
Mass spectrometry (MS) is an emerging tool in multiple myeloma that detects and quantifies monoclonal proteins in the peripheral blood with sensitivity several orders of magnitude greater than conventional serum protein electrophoresis and immunofixation. Both intact light chain (top-down) and clonotypic peptide (bottom-up) MS approaches have demonstrated sensitivity comparable to-or even surpassing-BM-based assessments using next generation flow cytometry or sequencing. However, due to the delayed clearance of paraproteins, MS may be less informative for early response assessment, underscoring the need to define the optimal timing for evaluation.
View Article and Find Full Text PDF